According to Zhitong Finance App News, Fosun Pharmaceutical (02196.HK) issued an announcement. Based on confidence in the Group's development prospects and recognition of intrinsic value, according to the general authorization granted by the company's shareholders at the company's annual general meeting of shareholders, the H share class shareholders' meeting and the Class A share shareholders' meeting held on June 16, 2026, to repurchase H shares, and with the approval of the board of directors, the company plans to repurchase H shares within 12 months from August 27, 2026. The company will determine the purpose of such repurchased H shares based on factors such as H share repurchase authorization and market conditions, including but not limited to cancelling the repurchased H shares or holding them as treasury shares.

According to Zhitong Finance App News, Fosun Pharmaceutical (02196.HK) issued an announcement. Based on confidence in the Group's development prospects and recognition of intrinsic value, according to the general authorization granted by the company's shareholders at the company's annual general meeting of shareholders, the H share class shareholders' meeting and the Class A share shareholders' meeting held on June 16, 2026, to repurchase H shares, and with the approval of the board of directors, the company plans to repurchase H shares within 12 months from August 27, 2026. The company will determine the purpose of such repurchased H shares based on factors such as H share repurchase authorization and market conditions, including but not limited to cancelling the repurchased H shares or holding them as treasury shares.